MiCheck® Prostate

MiCheck® Prostate LDT is intended for use as an aid to clinicians in the decision to proceed to prostate biopsy in patients with an abnormal PSA.

  • MiCheck® Prostate provides an estimate of the risk of aggressive prostate cancer.
  • MiCheck® Prostate has demonstrated the ability to differentiate aggressive from non-aggressive cancer and no cancer.
  • MiCheck® Prostate demonstrates a compelling advantage in specificity over existing products, outperforming the benchmark PSA test as well as other tests such as % free PSA and the Prostate Health Index (PHI) in a head-to-head comparison.
  • The lack of specificity of other tests has led to criticism due to the resulting unnecessary biopsies. MiCheck® Prostate helps fill this substantial unmet clinical need by allowing a reduction in number of biopsies while minimising the risk of missing out aggressive prostate cancer cases.
MiCheck® Prostate also offers:
Ease of use – blood collection made at the same time as the blood draw for a PSA test.
No interruption to the clinician’s current workflow.
Clear clinical utility – single page well-defined report to help the clinician determine whether the patient needs a biopsy or future follow-up in the coming months.
Timely delivery of results – ready for the patient’s next visit to the clinician.
Dominant health economics in comparison to standard of care.
✔ Early availability as a LDT through a CLIA certified high complexity laboratory.

Achievements

N

2020

Laboratory Developed MiCheck® Prostate Cancer Test Roll-out

N

2020

MiCheck® Pancreatic Cancer Study Commenced

N

2018

Completed MiCheck® Prostate Cancer Prospective Trial

N

2016

Awarded Accelerating Commercialization Grant to Further Product Development

N

2014

Clinical Validation Studies for MiCheck® Prostate Cancer Commenced

N

2011

Received Venture Capital Funding for Commercialization

N

2009

Showed Antibody Binding to Prostate Cancer Cells

N

2007

Minomic Formed to Pursue Opportunity in Biomarkers Based on MIL-38 Monoclonal Antibody

2015 Eureka Prize

Excellence in Interdisciplinary Scientific Research

Major Australian prize for innovation awarded to our CEO, Brad Walsh, and university collaborators.

Find Out More Information

  • About our highly effective prostate cancer blood test >More
  • About how your company and Minomic could partner to deliver better prostate cancer diagnostics >More 

7 + 4 =

Address Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 
Australia Phone International +612 9850 4000 In Australia 02 9850 4000 Compare your time zone with Sydney here Email info@minomic.com
Finding Us We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.

Headquarters of Minomic

Privacy Policy